The role of selected plant materials in reducing blood cholesterol levels
DOI:
https://doi.org/10.12775/HERB.2025.007Keywords
cholesterol, phytotherapy, clinical trialsAbstract
High blood cholesterol levels are generally considered as a risk factor for the development of atherosclerosis, which increases the likelihood of cardiovascular events. Treatment of hypercholesterolemia is often based on pharmacotherapy, with statin drugs commonly used. Natural raw materials are also useful in reducing cholesterol levels. A review of current scientific publications (PubMed, Google Scholar) related to the effect of selected natural substances on the lipid profile was conducted. Monacolin K, berberine, bergamot orange fruit and artichoke leaf are safe and effective alternatives to statin drugs or other drugs that
reduce cholesterol levels. They can also be a supporting element in pharmacotherapy of hypercholesterolemia. A review of available data confirms that they help reduce cholesterol levels and do not show significant adverse effects.
References
[1] Wnęk D., Cholesterol – funkcje, źródła, frakcje, stężenie, Medycyna Praktyczna, 2023, https://www.mp.pl/pacjent/dieta/zasady/117035,cholesterol-funkcje-zrodla-frakcje-stezenie (dostęp 1.08.2024).
[2] Heman P., Frakcje cholesterolu i trójglicerydy – panel lipidowy, Medycyna Praktyczna, 2023, https://www.mp.pl/pacjent/cholesterol/hipercholesterolemia/103924,cholesterol-i-triglicerydy-panel-lipidowy (dostęp 1.08.2024).
[3] Undas A., Guzik T., Szczeklik A., Miażdżyca i ryzyko sercowo-naczyniowe, [w:] Interna Szczeklika, (red.) P. Gajewski, Medycyna Praktyczna, 2015, s. 148-153.
[4] Tyrka A., Kopeć G., Statyny, Medycyna Praktyczna, 2023, https://www.mp.pl/pacjent/chorobawiencowa/leczenie/62423,statyny (dostęp 1.08.2024).
[5] Brown C.J., Chang L.,,. Hosomura N., Malmasi S., Morrison F., Shubina M., Lan Z.,Turchin A., Assessment of Sex Disparities in Nonacceptance of Statin therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk, JAMA Network Open, 2023, 6(2), e231047.
[6] Leki o działaniu hipolipemicznym, [w:] Kompendium farmakologii, (red.) W. Janiec, Wydawnictwo Lekarskie PZWL, Warszawa, 2021.
[7] Li Y.G., Zhang F., Wang Z.T., Hu Z.B., Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, 2004, 35(5), s. 1101–1112.
[8] Rozporządzenie Komisji (UE) 2022/860 z dnia 1 czerwca 2022 r. zmieniające załącznik III do rozporządzenia (WE) nr 1925/2006 Parlamentu Europejskiego i Rady w odniesieniu do monakolin ze sfermentowanego czerwonego ryżu.
[9] Cicero A.F.G., Fogacci F., Banach M., Red Yeast Rice for Hypercholesterolemia, Methodist DeBakey Cardiovascular Journal, 2019, 15(3), s. 192–199.
[10] Liasi E., Kantilafti M., Hadjimbei E., Chrysostomou S., Monacolin K supplementation in patients with hypercholesterolemia: A systematic review of clinical trials, Semergen, 2024, 50(4), s. 102156.
[11] Minamizuka T., Koshizaka M., Shoji M., Yamaga M., Hayashi A., Ide K., Ide S., Kitamoto T., Sakamoto K., Hattori A., Ishikawa T., Kobayashi J., Maezawa Y., Kobayashi K., Takemoto M., Inagaki M., Endo A., Yokote K., Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial, Asia Pacific Journal of Clinical Nutrition, 2021, 30(3), s. 424–435.
[12] Cicero A., Parini A., Rosticci M., Nutraceuticals and cholesterol-lowering action, International Journal of Cardiology, Metabolic & Endocrine, 2015, 6, s. 1–4.
[13] Cicero A.F.G., Fogacci F., Zambon A., Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar, Journal of the American College of Cardiology, 2021, 77(5), s. 620–628.
[14] Hadi A., Arab A., Ghaedi E., Rafie N., Miraghajani M., Kafeshani M., Barberry (Berberis vulgaris L.) is a safe approach for management of lipid parameters: A systematic review and meta‐analysis of randomized controlled trials, Complementary Therapies
in Medicine, 2019, 43, s. 117–124.
[15] Lazavi F., Mirmiran P., Sohrab G., Nikpayam O., Angoorani P., Hedayati M., The barberry juice effects on metabolic factors and oxidative stress in patients with type 2 diabetes: A randomized clinical trial, Complementary Therapies in Clinical Practice, 2018, 31, s. 170–174.
[16] Derosa G., D’Angelo A., Romano D., Maffioli P., Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial, International Journal of Molecular Science, 2017, 18(2), s. 343.
[17] Derosa G., Bonaventura A., Bianchi L., Romano D., D’Angelo A., Fogari E., Maffioli P., Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients, Expert Opinion on Biological Therapy, 2013, 13(11), s. 1495–1506.
[18] Derosa G., Romano D., D’Angelo A., Maffioli P., Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial, Phytomedicine, 2015, 22(2), s. 231–237.
[19] Derosa G., D’Angelo A., Maffioli P., The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus, Clinical Nutrition, 2016, 35(5), s. 1091–1095.
[20] Guarino G., Strollo F., Carbone L., Della Corte T., Letizia M., Marino G., Gentile S., Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes, Journal of Biological Regulators and Homeostatic Agents, 2017, 31(2), s. 495–502.
[21] Cicero A.F.G., Fogacci F., Bove M., Giovannini M., Veronesi M., Borghi C., Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease, the American Journal of Cardiology, 2019,123(4), s. 588–591.
[22] Bundy R., Walker A.F., Middleton R.W., Wallis C., Simpson H.C., Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: A randomized, double blind placebo controlled trial, Phytomedicine, 2008, 15(9), s. 668–675.
[23] Rondanelli M., Giacosa A., Opizzi A., Faliva M.A., Sala P., Perna S., Bombardelli E., Beneficial effects of artichoke leaf extract supplementation on increasing HDL-cholesterol in subjects with primary mild hypercholesterolaemia: a double-blind, randomized, placebo-controlled trial, International Journal of Food Sciences and Nutrition, 2013, 64(1), s. 7–15.
[24] Sahebkar A., Pirro M., Banach M., Mikhailidis D.P., Atkin S.L., Cicero A.F.G., Lipidlowering activity of artichoke extracts: A systematic review and meta-analysis, Critical Reviews in Food Science and Nutrition, 2018, 58(15), s. 2549–2556.
[25] Fogacci F., Giovannini M., Di Micoli A., Fiorini G., Grandi E., Borghi C., Cicero A.F.G., A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effect of a Dietary Supplement Containing Dry Artichoke and Bergamot Extracts on Metabolic and Vascular Risk Factors in Individuals with Suboptimal Cholesterol Levels, Nutrients, 2024, 16(11), s. 1587.
[26] Riva A., Petrangolini G., Allegrini P., Perna S., Giacosa A., Peroni G., Faliva M.A., Naso M., Rondanelli M., Artichoke and Bergamot Phytosome Alliance: A Randomized Double Blind Clinical Trial in Mild Hypercholesterolemia, Nutrients, 2021, 14(1), s. 108.
[27] Rondanelli M., Peroni G., Riva A, Petrangolini G., Allegrini P., Fazia T., Bernardinelli L., Naso M., Faliva M.A., Tartara A., Gasparri C., Infantino V., Perna S., Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial, Phytotherapy Research, 2021, 35(4), s. 2045–2056.
[28] Lamiquiz-Moneo I., Giné-González J., Alisente S., Bea A.M., Pérez-Calahorra S., Marco-Benedí V., Baila-Rueda L., Jarauta E., Cenarro A., Civeira F., Mateo-Gallego R., Effect of bergamot on lipid profile in humans: A systematic review; Critical Reviews in Food Science and Nutrition, 2020, 60(18), s. 3133–3143.
[29] WHO Traditional Medicine Strategy 2014–2023, World Health Organization 2013, https://www.who.int/publications/i/item/9789241506096 (dostęp 1.08.2024).
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 226
Number of citations: 0
